CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Saint-médard, Belgium

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

    Phase

    1/2

    Span

    203 weeks

    Sponsor

    Immunocore Ltd

    Anderlecht

    Recruiting

  • A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

    Phase

    N/A

    Span

    80 weeks

    Sponsor

    Takeda

    Anderlecht

    Recruiting

  • Transfusion Surveillance in Anaesthesia

    the aim of this register is to collect exhaustively the different data available surrounding a transfusion act in the context of an active haemorrhage. The aim is to allow different modelling and analysis related to emergency transfusion. Patients will be informed at the time of the anaesthesia consultation about the inclusion in the registry. The data will be collected from the patients' files by the investigators of the centre without modifying their management. The data collection period will not exceed the period of acute management.

    Phase

    N/A

    Span

    435 weeks

    Sponsor

    Erasme University Hospital

    Anderlecht

    Recruiting

  • Comparison of Skeletal Effects of Herbst and Invisalign MA in Growing Patients With KLass II Malocclusion

    Precise description of study methodology. For each group, a sample of +- 15 patients with class 2 malocclusion aged between 9 and 15 years will be collected for this prospective study who presented for an initial orthodontic consultation between October 2022 and july 20262 at ULB's Erasme Hospital. Each patient will be treated with Invisalign MA or the Herbst appliance by residents of the orthodontic program directed by P. Maria Orellana Inclusion criteria included a Class II skeletal malocclusion with an ANB greater than 4°; (In the case of a Class 2 Division 2 malocclusion, the retroclined upper incisors will be proclined to obtain an overjet allowing mandibular advancement. If the patient has a transverse deficit, palatal expansion will be performed before treatment with aligners and during treatment in herbst cases.) Class II molar and canine relationship and CVM2/CVM3 cervical vertebral maturation. Informed consent forms in the patient's native language will be submitted before the start of each treatment. Only a profile cephalometry will be taken in the patients considered for this study at the time of the initial consultation. This will avoid unnecessary radiographic exposure, and a panoramic view of each patient will be extracted from a CBCT using the FDA-approved BlueskyBio program. Aligners or Herbst appliance for orthodontic treatment will be fabricated on the basis of a 3D optical scan (Itero), after which patients will begin treatment. Levelling of the Spee curve, derotation of (pre)molars and palatal incisors in the case of class 2 division 2 malocclusion will be carried out before the mandibular advancement stage if necessary in the Aligner group. A full-face ultra-low dose CBCT scan will be performed on all included subjects before the mandibular advancement stage according to a strict protocol by a certified physician. Active mandibular advancement will be continued till a KLass I molar relationship is obtained and will be followed by 2 months without mandibular advancement to allow the mandibular condyles to take a central position in the condylar fossae. After this 2-month period, a second CBCT scan will be performed (T2), with a minimal time interval of one year between the two CBCT scans, using the same protocol. CBCTs will be acquired using a Promax Mid 90 Kv with settings of 90 kV and 8.9 mAS, and tube current modulation will be used to enable patient-specific dose reduction. After the second CBCT, orthodontic treatment will be continued until completion, and retention and regular post-treatment follow-up will be scheduled for each patient. The superposition of CBCT (T1) and (T2) images on the anterior cranial base will be used to determine exact mandibular lengthening, condylar displacement, mandibular rotation and chin displacement using the following methodology described and developed by Hugo. De Clerck in 2009.

    Phase

    1

    Span

    187 weeks

    Sponsor

    Université Libre de Bruxelles

    Brussels

    Recruiting

    Healthy Volunteers

  • First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

    Phase

    1

    Span

    179 weeks

    Sponsor

    OnKure, Inc.

    Anderlecht

    Recruiting

  • First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

    Phase

    1

    Span

    377 weeks

    Sponsor

    Bayer

    Anderlecht

    Recruiting

  • Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma

    Phase

    2/3

    Span

    166 weeks

    Sponsor

    PharmaMar

    Anderlecht

    Recruiting

  • Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus

    All pH-MII performed in UZ Brussel are already reviewed manually according to the Wingate con-sensus and interpreted according to the Lyon consensus. In this study, we will prospectively categorise the reasons for discarding reflux episodes identified by automated analysis during the manual review according to the Wingate consensus, as well as the impact on different parameters related to the interpretation of pH-MII. Based on comments received to our retrospective study, we will evaluate possible confounders to the interpretation, including the indication for referral for pH-MII, symptom severity, use of PPI during pH-MII.

    Phase

    N/A

    Span

    131 weeks

    Sponsor

    Universitair Ziekenhuis Brussel

    Anderlecht

    Recruiting

  • Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    Phase

    3

    Span

    387 weeks

    Sponsor

    GlaxoSmithKline

    Anderlecht

    Recruiting

  • Clinical Trial of PM54 in Advanced Solid Tumors Patients.

    Phase

    1

    Span

    153 weeks

    Sponsor

    PharmaMar

    Anderlecht

    Recruiting

1-10 of 526
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information